IP Library › Granted Patent US 12,433,908
Granted Patent B2
US 12,433,908 · App. 18/060,257 · Granted Oct 7, 2025

Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

Inventors: Ryan Dellinger (Azusa, CA); Troy Rhonemus (Mission Viejo, CA); Mark Morris (Irvine, CA); Dietrich Conze (Garrett Park, MD); Amy Boileau (Libertyville, IL)
Assignee: ChromaDex Inc.
A61K31/706A23L33/10A23L33/15A23L33/19A23L33/30A23L33/40A61K31/4415A61K31/455A61K31/51A61K31/525A61K31/7064A61K45/06A61K47/42A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,908
App. No.
18/060,257
Granted
Oct 7, 2025
Kind
B2
Abstract

Infant formula compositions and methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Claims (14)

1. An infant formula composition comprising at least one nicotinyl riboside compound, or salt thereof, wherein said nicotinyl riboside compound comprises nicotinamide riboside (NR, I), and optionally at least one nicotinyl riboside compound selected from the group consisting of nicotinic acid riboside (NAR, II), reduced nicotinamide riboside (NRH, IV), reduced nicotinic acid riboside (NARH, V), nicotinamide riboside triacetate (NRTA, VI), nicotinic acid riboside triacetate (NARTA, VII), reduced nicotinamide riboside triacetate (NRH-TA, VIII), and reduced nicotinic acid riboside triacetate (NARH-TA, IX); together with an acceptable excipient, diluent, or carrier, wherein the total amount of nicotinyl riboside compound or salt thereof in the infant formula composition is about 1,500 ug to about 10,000 ug per 100 kilocalories of the infant formula composition.

2. The infant formula composition of claim 1 , further comprising at least one protein selected from the group consisting of whey and casein.

3. The infant formula composition of claim 2 , further comprising about 1.8 g-4.5 g protein per 100 kilocalories infant formula composition.

4. The infant formula composition of claim 1 , further comprising at least one vitamin selected from the group consisting of vitamin B1 (thiamine, XI), vitamin B2 (riboflavin, XII), and vitamin B6 (pyridoxine, XIII).

5. The infant formula composition of claim 4 , further comprising, for every 300 ug nicotinamide riboside (NR, I) compound in the infant formula composition, about 40 ug vitamin B1, about 60 ug vitamin B2, and about 35 ug vitamin B6.

6. The infant formula composition of claim 1 , further comprising calcium, phosphorus, magnesium, zinc, manganese, copper, sodium, potassium, chloride, iron, selenium, chromium, molybdenum, iodine, taurine, carnitine, or choline.

7. The infant formula composition of claim 1 , further comprising at least one protein selected from the group consisting of whey and casein; at least one vitamin selected from the group consisting of vitamin B1 (thiamine, XI), vitamin B2 (riboflavin, XII), and vitamin B6 (pyridoxine, XIII); and at least one of calcium, phosphorus, magnesium, zinc, manganese, copper, sodium, potassium, chloride, iron, selenium, chromium, molybdenum, iodine, taurine, carnitine, or choline.

8. The infant formula composition of claim 1 , further comprising an excipient, a binder, a disintegrating agent, a lubricant, a sweetening agent, a flavoring agent, or a coating.

9. The infant formula composition of claim 1 , wherein said composition is in powder or in liquid form.

10. An infant formula composition comprising at least one nicotinyl riboside compound, or salt thereof, wherein the nicotinyl riboside comprises nicotinamide riboside (NR, I), and optionally at least one nicotinyl riboside compound selected from the group consisting of nicotinic acid riboside (NAR, II), reduced nicotinamide riboside (NRH, IV), reduced nicotinic acid riboside (NARH, V), nicotinamide riboside triacetate (NRTA, VI), nicotinic acid riboside triacetate (NARTA, VII), reduced nicotinamide riboside triacetate (NRH-TA, VIII), and reduced nicotinic acid riboside triacetate (NARH-TA, IX); together with an acceptable excipient, diluent, or carrier, wherein when said at least one nicotinyl riboside compound is a salt, a counterion is selected from the group consisting of calcium, magnesium, potassium, sodium, zinc, N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), tromethamine (tris (hydroxymethyl) aminomethane), procaine, fluoride, chloride, bromide, iodide, formate, acetate, ascorbate, benzoate, carbonate, citrate, carbamate, formate, gluconate, lactate, glycolate, malate, tartrate, glucuronate, maleate, fumarate, pyruvate, methane sulfonate, benzene sulfonate, p-toluenesulfonate, salicylate, galactarate, galacturonate, methyl bromide, methyl sulfate, nitrate, phosphate, diphosphate, succinate, sulfate, trifluoromethanesulfonate, trifluoroacetate, propionate, butyrate, glutamate, aspartate, tribromomethanesulfonate, trichloromethanesulfonate, and hydrogen carbonate,

wherein the amount of nicotinyl riboside compound or salt thereof in the infant formula composition is about 1,500 ug to about 10,000 ug per 100 kilocalories of the infant formula composition.

11. The infant formula composition of claim 10 , wherein said nicotinyl riboside compound or salt thereof is a salt of acetic acid or a salt of propionic acid.

12. The infant formula composition of claim 10 , further comprising, for every 300 ug nicotinamide riboside (NR, I) compound in the infant formula composition, about 40 ug vitamin B1, about 60 ug vitamin B2, and about 35 ug vitamin B6.

13. The infant formula composition of claim 10 , wherein said composition is in powder or in liquid form.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2022
From: DELLINGER, RYAN; RHONEMUS, TROY; MORRIS, MARK; CONZE, DIETRICH; BOILEAU, AMY
To: CHROMADEX INC.
Reel/Frame 061925/0969 →
Continuity (4)
Division 17114864 · Dec 8, 2020
Continuation 15488215 · Apr 14, 2017
Provisional Application 62322460 · Apr 14, 2016
Related Publication 20230201233A1 · Jun 29, 2023
References Cited (40)
US 20060002914A1 · Milbrandt et al. · 2006 [cited by applicant]
US 20070117765A1 · Sauve et al. · 2007 [cited by applicant]
US 20090311379A1 · Petschow et al. · 2009 [cited by applicant]
US 20100104686A1 · Rosales et al. · 2010 [cited by applicant]
US 20100104696A1 · Banavara et al. · 2010 [cited by applicant]
US 20100104721A1 · Legan et al. · 2010 [cited by applicant]
US 20100104727A1 · Gonzalez et al. · 2010 [cited by applicant]
US 20100316619A1 · Wittke · 2010 [cited by applicant]
US 20150119322A1 · Chichlowski et al. · 2015 [cited by applicant]
US 20150237902A1 · Rosado et al. · 2015 [cited by applicant]
US 20170204131A1 · Szczepankiewicz et al. · 2017 [cited by applicant]
WO 2007061798A2 · 2007 [cited by applicant]
WO 2013186355A1 · 2013 [cited by applicant]
WO 2014042503A1 · 2014 [cited by applicant]
“ChromaDex(R) Introduces Niagen(TM)—The First and Only Commercially Available Nicotinamide Riboside.” Press Release [online]. Chromadex Corporation, May 29, 2013 [retrieved on Jun. 14, 2017]. Retrieved from the Internet… [cited by applicant]
Horwitt, M.K. “Niacin-Tryptophan Relationships in the Development of Pellagra”, 3 Am. J. Clinical Nutrition pp. 244-245 (1955). [cited by applicant]
Horwitt, M.K. et al., “Niacin-tryptophan relationships for evaluating niacin equivalents,” Am. J. Clinical Nutrition 34, pp. 423-427 (1981). [cited by applicant]
Institute of Medicine of Medicine, Food & Nutrition Board, “6. Niacin,” Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline, National Academi… [cited by applicant]
Bieganowski, P. et al. “Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans”, Cell, vol. 117, pp. 495-502 (2004). [cited by applicant]
Hathcock, J.N. “Niacin: Nicotinic Acid, Nicotinamide, and Inositol Hexanicotinate,” Vitamin & Mineral Safety (Douglas Mackay et al., eds., 3d ed., Council for Responsible Nutrition (CRN) 2014), pp. 66-79, available at h… [cited by applicant]
European Food Safety Authority, “Draft Scientific Opinion on Dietary Reference Values for niacin,” EFSA J. (2014), 12(7):3759, 42 pages available at http://www.efsa.europa.eu/efsajournal/. [cited by applicant]
Canto, C. et al., “NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus,” Cell Metabolism, 23 pages, (2015). [cited by applicant]
National Institutes of Health, U.S. Dep't of Agriculture, “Unit Conversions,” https://dietarysupplementdatabase.usda.nih.gov/Conversions.php (last updated Aug. 14, 2017), 3 pages. [cited by applicant]
Chi, J. et al. “Nicotinamide riboside, a trace nutrient in foods, is a Vitamin B3 with effects on energy metabolism and neuroprotection”, Current Opinion in Clin. Nutrition Metabolic Care, 16:657-661 (2013). [cited by applicant]
Benyo, Z. et al., “GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing”, J. Clinical Investigation, 115 (12):3634-3640 (2005). [cited by applicant]
Canto, C. et al., “The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity”, Cell Metabolism 15, 838-847 (2012). [cited by applicant]
EFSA Panel on Dietetic Products, et al., “Safety of D-ribose as a novel food pursuant to Regulation (EU) 2015/2283,” EFSA Journal, Scientific Opinion (2018); 16(5):5265 (pp. 1-28). [cited by applicant]
Johnson, R.W. et al., “Pyridine Nucleotide Chemistry. A New Mechanism for the Hydroxide-Catalyzed Hydrolysis of the Nicotinamide-Glycosyl Bond,” J. American Chemical Society (1988); 110: 2257-2263. [cited by applicant]
Trammell, S.A.J. et al., “Nicotinamide Riboside is a Major NAD+ Precursor Vitamin in Cow Milk”, The Journal of Nutrition (2016); 146(5):957-63, doi: 10.3945/jn. 116.230078. [cited by applicant]
Gross, M. et al. “Serum levels of glucose, insulin, and C-peptide during long-term D-ribose administration in man,” Klinische Wochenschrift 69(1): 31-36 (1991); https://link.springer.com/article/10.1007/BF01649054 [Abst… [cited by applicant]
Han, X. et al., “NAD+ Ameliorates Inflammation-Induced Epithelial Barrier Dysfunction in Cultured Enterocytes and Mouse Ileal Mucosa” J. Pharmacol. Exper. Therapeut. 307(2):443-449 (2003). [cited by applicant]
Capuzzi, D. M. et al., “Niacin Dosing: Relationship to Benefits and Adverse Effects”, Current Atherosclerosis Reports, 2000, vol. 2, pp. 64-71 (Year: 2000). [cited by applicant]
Yang, T. et al., “Syntheses of Nicotinamide Riboside and Derivatives: Effective Agents for Increasing Nicotinamide Adenine Dinucleotide Concentrations in Mammalian Cells”, J. Med. Chem., 2007, vol. 50, pp. 6458-6461 (Ye… [cited by applicant]
Bogan, K. L. et al., “Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAO+ Precursor Vitamins in Human Nutrition”, Annu. Rev. Nutr., 2008, vol. 28, pp. 115-130. [cited by applicant]
Australian National Health and Medical Research Council (NHMRC), “Niacin”, Nutrient Reference Values for Australia and New Zealand, pp. 79-84, 2006. [cited by applicant]
Rios-Covian, D. et al. “Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health,” Frontiers in Microbiology, Feb. 2016, vol. 7, Article 185, 9 pages. [cited by applicant]
“ChromaDex® Announces Deal for Its Recently Launched Niagen™ Nicotinamide Riboside With Thorne Research, Cision PR newswire.” <https://www.prnewswire.com/news-releases/chromadex-announces-deal-for-its-recently-launched-… [cited by applicant]
Han, X. et al., “NAD+ Ameliorates Inflammation-induced Epithelial Barrier Dysfunction in Cultured Enterocytes and Mouse Ileal Mucosa”, JPET Fast Forward, vol. 56556, Sep. 15, 2003, pp. 1-29, DOI:10.1124/jpet.103.056556. [cited by applicant]
International Searching Authority/US Patent and Trademark Office, International Search Report and Written Opinion issued in related application PCT/US2017/027755 on Jul. 21, 2017, 9 pages. [cited by applicant]
European Patent Office, European Search Report and Search Opinion issued in related application 17783307.6 on Nov. 19, 2017, 8 pages. [cited by applicant]